D. V. Ergakov
D. V. Ergakov has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Aleksei G. Martov
Central Clinical Hospital of Civil Aviation”; Medical and Biological University of Innovation and Continuing Education — Burnazyan Federal Medical Biophysical Center of the FMBA of Russia; Medical Scientific and Educational Center — Lomonosov Moscow State University (Lomonosov University)
8 shared publications - A. S. Andronov
Department of Urology and Andrology of Medical and Biological University of Innovation and Continuous Education of Federal Medical Biophysical Center named after A.I. Burnazyan of Federal Medical and Biological Agency of Russia Moscow, head of the urological department №1 at the urological center at the Central clinical hospital of Civil Aviation, Moscow, Russia
2 shared publications - A S Andronov
GBUZ City clinical hospital named after D.D. Pletnev of the Health Department c. Moscow, Moscow, Russia
1 shared publication - A. B. Novikov
Multidisciplinary Medical center of the Central Bank of the Russian Federation
1 shared publication A.A. Kamalov
1 shared publicationA.I. Burnazyan Federal State Medical Center Of Fmba Of Russia
1 shared publication
Latest Publications
- Open Access
- 15 November 2023
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 19 (3) , 60-68-68
Clinical use of high dose-rate brachytherapy in treatment of patients with localized prostate cancer and infravesical obstruction
Background. High dose-rate brachytherapy is a new method of interstitial radiation therapy for treatment of localized prostate cancer. The difference from low dose therapy is temporary implantation of radiation sources with targeted high dose-rate irradiation of the affected organ.Aim. To evaluate 3-year effectiveness and safety of high dose-rate brachytherapy in patients with infravesical obstruction. Materials and methods. Between January of 2017 and December of 2019 at the Central Clinical Hospital “RZD-medicine”, 49 patients (mean age 67.8 ± 7.5 years) with verified prostate cancer diagnosis underwent high dose-rate brachytherapy in the regimen of 2 sessions of 15 Gy with 192Ir source. The inclusion criteria were disease stage ≤сТ2с, Gleason score ≤7. Patients were divided into 2 groups: 1st – patients with incidental prostate cancer (n = 21) who previously (more than 6 months ago, mean time 9.4 ± 2.4 months) underwent transurethral prostatectomy; 2nd – patients with verified prostate cancer (mean prostate volume 56 cm3) and obstructive symptoms without previous transurethral prostatectomy (n = 28).Results. In both groups, no intraoperative complications were observed. In 6 (28 %) patients of the 1st group and 2 patients of the 2nd group, grade II genitourinary toxicity in the form of moderate dysuria and nocturia was observed. Acute gastrointestinal toxicity was observed in 3 (14 %) patients of the 1st group, in the 2nd group such complications were absent. In the 2nd group during the postoperative period after the 2nd session, 4 patients (14 %) experienced acute urinary retention requiring cystostomy.Conclusion. High dose-rate brachytherapy is a safe and effective radical treatment method for patients with localized prostate cancer with obstructive symptoms who have contraindications for surgical treatment.
- 15 November 2023
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 19 (3) , 60-68-68
Open AccessClinical use of high dose-rate brachytherapy in treatment of patients with localized prostate cancer and infravesical obstruction
Background. High dose-rate brachytherapy is a new method of interstitial radiation therapy for treatment of localized prostate cancer. The difference from low dose therapy is temporary implantation of radiation sources with targeted high dose-rate irradiation of the affected organ.Aim. To evaluate 3-year effectiveness and safety of high dose-rate brachytherapy in patients with infravesical obstruction. Materials and methods. Between January of 2017 and December of 2019 at the Central Clinical Hospital “RZD-medicine”, 49 patients (mean age 67.8 ± 7.5 years) with verified prostate cancer diagnosis underwent high dose-rate brachytherapy in the regimen of 2 sessions of 15 Gy with 192Ir source. The inclusion criteria were disease stage ≤сТ2с, Gleason score ≤7. Patients were divided into 2 groups: 1st – patients with incidental prostate cancer (n = 21) who previously (more than 6 months ago, mean time 9.4 ± 2.4 months) underwent transurethral prostatectomy; 2nd – patients with verified prostate cancer (mean prostate volume 56 cm3) and obstructive symptoms without previous transurethral prostatectomy (n = 28).Results. In both groups, no intraoperative complications were observed. In 6 (28 %) patients of the 1st group and 2 patients of the 2nd group, grade II genitourinary toxicity in the form of moderate dysuria and nocturia was observed. Acute gastrointestinal toxicity was observed in 3 (14 %) patients of the 1st group, in the 2nd group such complications were absent. In the 2nd group during the postoperative period after the 2nd session, 4 patients (14 %) experienced acute urinary retention requiring cystostomy.Conclusion. High dose-rate brachytherapy is a safe and effective radical treatment method for patients with localized prostate cancer with obstructive symptoms who have contraindications for surgical treatment.
- Open Access
- 4 April 2023
- Published by Rostov State Medical University in Urology Herald
- Vol. 11 (1) , 59-69
Ejaculation-sparing enucleation of benign prostate hyperplasia: is it almost feasible?
Introduction. Patients often request maintenance of antegrade ejaculation, and try to find the clinic, surgeon, and treatment to store it. Despite an established technique, the long-term results of ejaculation-sparing operations at a large prostate volume remain unstable. This is not allowed to give patients a guarantee in maintaining this component in their sexual life.Objective. To evaluate the frequency of ejaculation maintenance after laser ejaculatory-sparing prostate enucleation.Materials & methods. Since 2017 ejaculation-sparing laser enucleations have been performed in prostate volume (V pr > 80 cc) in 84 patients. Fifty-four patients (64%) had three lobes benign prostate hyperplasia (BPH) and two lobes — 30 patients (36%). Preoperative voiding parameters were IPSS score — 21.0 ± 2.7, QoL — 4.8 ± 0.6, residual urine volume (V res) — 139 ± 43 mL, Q max — 8.1 ± 2.0 mL. We estimate the result as positive if antegrade ejaculation remained after intervention. If ejaculation volume decreased, then as partially positive and negative — ejaculation was absent postoperatively. We conducted questionnaire and follow-up examination 3 – 6 months after intervention.Results. Thulium-fiber laser enucleations have been performed in all cases without any serious complications. Followup 3 – 6 months after operation showed V pr — 29 ± 4 cc, V res — 19 ± 17 mL, Q max — 19.1 ± 3.1 mL/sec. IPSS score — 8.1 ± 1.9 and QoL — 2.6 ± 0.7. There are the following technical remarks: 1) tissue-sparing in the verumontanum; 2) no or minor mechanical tissue tension during enucleation; 3) avoid additional resection in the bladder neck; 4) refuse total coagulation; 5) no urethral catheter tension after operation; 6) catheter balloon inflow only in the bladder, not in the fossa. Antegrade ejaculation has stored at 17 (20%) patients, partial ejaculation — at 34 (40%) patients, so overall efficacy is 60%. The presence of a median lobe is shown to be negative prognostic factor due to the absence of full antegrade ejaculation in all cases. A partial ejaculation was achieved at 21 patients. Based on the obtained results we have optimized the three-lobe prostate enucleation technique. Four from our initial 7 patients had full storage of ejaculation and 3 — partial.Conclusion. The possibility of BPH laser surgery to store ejaculation function at the request of the patients is modest. The presence of the median lobe makes the full ejaculation-sparing impossible. In cases of two lobes BPH full storage of the ejaculation was at 57% and partial at 43%, respectively. The following evaluation of the described technique is mandatory.
- 4 April 2023
- Published by Rostov State Medical University in Urology Herald
- Vol. 11 (1) , 59-69
Open AccessEjaculation-sparing enucleation of benign prostate hyperplasia: is it almost feasible?
Introduction. Patients often request maintenance of antegrade ejaculation, and try to find the clinic, surgeon, and treatment to store it. Despite an established technique, the long-term results of ejaculation-sparing operations at a large prostate volume remain unstable. This is not allowed to give patients a guarantee in maintaining this component in their sexual life.Objective. To evaluate the frequency of ejaculation maintenance after laser ejaculatory-sparing prostate enucleation.Materials & methods. Since 2017 ejaculation-sparing laser enucleations have been performed in prostate volume (V pr > 80 cc) in 84 patients. Fifty-four patients (64%) had three lobes benign prostate hyperplasia (BPH) and two lobes — 30 patients (36%). Preoperative voiding parameters were IPSS score — 21.0 ± 2.7, QoL — 4.8 ± 0.6, residual urine volume (V res) — 139 ± 43 mL, Q max — 8.1 ± 2.0 mL. We estimate the result as positive if antegrade ejaculation remained after intervention. If ejaculation volume decreased, then as partially positive and negative — ejaculation was absent postoperatively. We conducted questionnaire and follow-up examination 3 – 6 months after intervention.Results. Thulium-fiber laser enucleations have been performed in all cases without any serious complications. Followup 3 – 6 months after operation showed V pr — 29 ± 4 cc, V res — 19 ± 17 mL, Q max — 19.1 ± 3.1 mL/sec. IPSS score — 8.1 ± 1.9 and QoL — 2.6 ± 0.7. There are the following technical remarks: 1) tissue-sparing in the verumontanum; 2) no or minor mechanical tissue tension during enucleation; 3) avoid additional resection in the bladder neck; 4) refuse total coagulation; 5) no urethral catheter tension after operation; 6) catheter balloon inflow only in the bladder, not in the fossa. Antegrade ejaculation has stored at 17 (20%) patients, partial ejaculation — at 34 (40%) patients, so overall efficacy is 60%. The presence of a median lobe is shown to be negative prognostic factor due to the absence of full antegrade ejaculation in all cases. A partial ejaculation was achieved at 21 patients. Based on the obtained results we have optimized the three-lobe prostate enucleation technique. Four from our initial 7 patients had full storage of ejaculation and 3 — partial.Conclusion. The possibility of BPH laser surgery to store ejaculation function at the request of the patients is modest. The presence of the median lobe makes the full ejaculation-sparing impossible. In cases of two lobes BPH full storage of the ejaculation was at 57% and partial at 43%, respectively. The following evaluation of the described technique is mandatory.
- Open Access
- 10 December 2022
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 18 (3) , 123-127-127
Upper tract urothelial carcinoma: can the tumor be removed en bloc?
Diagnosis and treatment of upper tract urothelial carcinoma (UTUC) remain important problems of clinical urology. UTUC en bloc i.e. in one-piece removal during organ-sparing surgery is still hardly possible. The most typical endourological operations are either electrosurgery, holmium or thulium YAG laser tumor vaporization.We present a clinical case of ureteroscopic en bloc UTUC removal using a new super pulse thulium fiber laser (SPTFL, FiberLase U3). Recent innovations and trends in this field are also discussed. The technical steps of en bloc ureteroscopic tumor removal allowing for diagnosis verification, identification of pT stage and surgical margin are described. The further innovations in laser UTUC removal include modulation of laser pulse length and development of the correlation between preoperative tumor characteristics and possibility of en bloc removal.
- 10 December 2022
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 18 (3) , 123-127-127
Open AccessUpper tract urothelial carcinoma: can the tumor be removed en bloc?
Diagnosis and treatment of upper tract urothelial carcinoma (UTUC) remain important problems of clinical urology. UTUC en bloc i.e. in one-piece removal during organ-sparing surgery is still hardly possible. The most typical endourological operations are either electrosurgery, holmium or thulium YAG laser tumor vaporization.We present a clinical case of ureteroscopic en bloc UTUC removal using a new super pulse thulium fiber laser (SPTFL, FiberLase U3). Recent innovations and trends in this field are also discussed. The technical steps of en bloc ureteroscopic tumor removal allowing for diagnosis verification, identification of pT stage and surgical margin are described. The further innovations in laser UTUC removal include modulation of laser pulse length and development of the correlation between preoperative tumor characteristics and possibility of en bloc removal.
- Open Access
- 25 September 2021
- Published by UroMedia LLC in Experimental and Сlinical Urology
- Vol. 14 (3) , 136-140
Clinical use of cytomedin in patients with prostate diseases
Introduction. The use of extracts of the prostate of animals is one of the main directions in the treatment of patients with diseases of the prostate. Most studies describe the experience of using these drugs in a small number of patients for a limited time period. The aim of this work was to summarize the long-term experience of using drugs of the cytomedin group in the treatment of a large number of patients with chronic prostatitis (CP) and benign prostatic hyperplasia (BPH). Materials and methods. Cytomedins were used in 487 patients with CP / BPH from January 2015 to December 2018. Indications: rehabilitation of patients after pancreatic biopsy (63 patients, 13%), cystoscopy and other endoscopic surgical interventions (189 patients, 39%), as well as conservative therapy of chronic inflammation associated with BPH (235 patients, 48%). If an infectious-inflammatory process was suspected, the following scheme was used: Vitaprost Plus 1 candle 1 time per day for 20 days, in the presence of irritative complaints, Vitaprost Forte was used 1 candle 1 time per day for 20 days, in other cases Vitaprost was prescribed 1 candle 1 time per day for 20 days ... The second component of the complex treatment was the use of the Vitaprost tablet form for 20 days, 1 ton 2 times a day. Before and after the appointment of therapy, the quality of life was monitored according to the data of the visual analogue scale (VAS), ultrasound examination of the pancreas (ultrasound) and laboratory parameters. The results of therapy were assessed as successful with an improvement in the quality of life, a decrease in the level of leukocytes, and a decrease in the volume of the pancreas by more than 10% from the initial level. Results. The total efficacy of cytomedin therapy was 39%. The greatest effectiveness of therapy was with the initial VAS less than 60 points out of 100; with more severe pain syndrome, the effectiveness was statistically significantly reduced to 32%. The initial detection of an inflammatory component with an increase in the level of leukocytes in laboratory tests statistically significantly increased the effectiveness of therapy 48 versus 24%. Cytomedin therapy was equally effective regardless of the prostate volume (36% versus 42% versus 38%, p> 0.05). A survey was conducted in 102 patients after Vitaprost-Forte / Vitaprost therapy, the results of which revealed a decrease in the I-PSS score from 18 ± 6.4 points to 12 ± 4 points (p> 0.05), in the group with combination therapy with alpha adrenergic blockers – 8 ± 3.2 points, p 0.05) versus 18 ± 3.4 points before treatment. Conclusions. the following prognostic criteria for the effectiveness of cytomedin therapy were determined: the level of the visual analogue scale is less than 60 out of 100 and the presence of a confirmed inflammatory component according to laboratory tests.
- 25 September 2021
- Published by UroMedia LLC in Experimental and Сlinical Urology
- Vol. 14 (3) , 136-140
Open AccessClinical use of cytomedin in patients with prostate diseases
Introduction. The use of extracts of the prostate of animals is one of the main directions in the treatment of patients with diseases of the prostate. Most studies describe the experience of using these drugs in a small number of patients for a limited time period. The aim of this work was to summarize the long-term experience of using drugs of the cytomedin group in the treatment of a large number of patients with chronic prostatitis (CP) and benign prostatic hyperplasia (BPH). Materials and methods. Cytomedins were used in 487 patients with CP / BPH from January 2015 to December 2018. Indications: rehabilitation of patients after pancreatic biopsy (63 patients, 13%), cystoscopy and other endoscopic surgical interventions (189 patients, 39%), as well as conservative therapy of chronic inflammation associated with BPH (235 patients, 48%). If an infectious-inflammatory process was suspected, the following scheme was used: Vitaprost Plus 1 candle 1 time per day for 20 days, in the presence of irritative complaints, Vitaprost Forte was used 1 candle 1 time per day for 20 days, in other cases Vitaprost was prescribed 1 candle 1 time per day for 20 days ... The second component of the complex treatment was the use of the Vitaprost tablet form for 20 days, 1 ton 2 times a day. Before and after the appointment of therapy, the quality of life was monitored according to the data of the visual analogue scale (VAS), ultrasound examination of the pancreas (ultrasound) and laboratory parameters. The results of therapy were assessed as successful with an improvement in the quality of life, a decrease in the level of leukocytes, and a decrease in the volume of the pancreas by more than 10% from the initial level. Results. The total efficacy of cytomedin therapy was 39%. The greatest effectiveness of therapy was with the initial VAS less than 60 points out of 100; with more severe pain syndrome, the effectiveness was statistically significantly reduced to 32%. The initial detection of an inflammatory component with an increase in the level of leukocytes in laboratory tests statistically significantly increased the effectiveness of therapy 48 versus 24%. Cytomedin therapy was equally effective regardless of the prostate volume (36% versus 42% versus 38%, p> 0.05). A survey was conducted in 102 patients after Vitaprost-Forte / Vitaprost therapy, the results of which revealed a decrease in the I-PSS score from 18 ± 6.4 points to 12 ± 4 points (p> 0.05), in the group with combination therapy with alpha adrenergic blockers – 8 ± 3.2 points, p 0.05) versus 18 ± 3.4 points before treatment. Conclusions. the following prognostic criteria for the effectiveness of cytomedin therapy were determined: the level of the visual analogue scale is less than 60 out of 100 and the presence of a confirmed inflammatory component according to laboratory tests.
- Open Access
- 25 December 2020
- Published by UroMedia LLC in Experimental and Сlinical Urology
- Vol. 13 (5) , 42-45
Endoscopic removal of a papillary tumor of the ureter in a patient with polyneoplasia
Introduction. Detection of metachronic tumors in patients who underwent radical surgery for oncological reasons is extremely important not only in oncology, but also in medicine in general. In this report, we present a case of clinical manifestation of urothelial carcinoma of the right ureter 21 months after the removal of melanoma and 6 months after radical prostatectomy. Materials and methods. A rare case of a 55-year-old man with a diagnosed polyneoplasia (primary multiple malignant tumors) is demonstrated. A patient with a history of melanoma of the left suprascapular region and prostate cancer diagnosed a year later, subsequently developed a papillary tumor of the right ureter 6 months after it. The tumor of the ureter manifested by macrohematuria. Examination revealed a right-sided ureterohydronephrosis. Results. Computed virtual chromoendoscopy-assisted ureteroscopy provided not only an accurate diagnosis and improved visualization of the tumor borders but also a holmium laser vaporization of the ureter. Follow-up of the patient in the next 5 years revealed recurrence neither of melanoma and prostate cancer, nor urothelial cancer of the right ureter or the bladder. Discussion. This clinical case is interesting due to the rare combination of three cancers in one patient within a relatively short time interval. The use of modern optical and computer technologies made it possible not only to carry out early diagnosis of papillary ureteral cancer, but also to carry out a more radical removal of the tumor. Conclusion. This observation illustrates the necessity of a thorough evaluation of cancer patients without adherence to the site of the primary disease.
- 25 December 2020
- Published by UroMedia LLC in Experimental and Сlinical Urology
- Vol. 13 (5) , 42-45
Open AccessEndoscopic removal of a papillary tumor of the ureter in a patient with polyneoplasia
Introduction. Detection of metachronic tumors in patients who underwent radical surgery for oncological reasons is extremely important not only in oncology, but also in medicine in general. In this report, we present a case of clinical manifestation of urothelial carcinoma of the right ureter 21 months after the removal of melanoma and 6 months after radical prostatectomy. Materials and methods. A rare case of a 55-year-old man with a diagnosed polyneoplasia (primary multiple malignant tumors) is demonstrated. A patient with a history of melanoma of the left suprascapular region and prostate cancer diagnosed a year later, subsequently developed a papillary tumor of the right ureter 6 months after it. The tumor of the ureter manifested by macrohematuria. Examination revealed a right-sided ureterohydronephrosis. Results. Computed virtual chromoendoscopy-assisted ureteroscopy provided not only an accurate diagnosis and improved visualization of the tumor borders but also a holmium laser vaporization of the ureter. Follow-up of the patient in the next 5 years revealed recurrence neither of melanoma and prostate cancer, nor urothelial cancer of the right ureter or the bladder. Discussion. This clinical case is interesting due to the rare combination of three cancers in one patient within a relatively short time interval. The use of modern optical and computer technologies made it possible not only to carry out early diagnosis of papillary ureteral cancer, but also to carry out a more radical removal of the tumor. Conclusion. This observation illustrates the necessity of a thorough evaluation of cancer patients without adherence to the site of the primary disease.
- Open Access
- 22 December 2020
- Published by QUASAR, LLC in Research and Practical Medicine Journal
- Vol. 7 (4) , 105-117
Stenting of the upper urinary tract: from bottom, from top, from side...
Internal stenting of the upper urinary tract is a widespread urological surgery. Its frequency in modern practice is high and continues to grow due to the widespread use of endourological, percutaneous, and laparoscopic interventions. The presence of a stent in the patient's body often leads to a decrease in the quality of life due to the occurrence of stent-dependent symptoms, which often requires urgent hospitalization. According to various data, they are registered in at least 80% of patients. The most common stent-dependent symptoms are frequent and / or painful urination, urge to mix (up to imperative), nocturia, pain in the lumbar region, macrohematuria. According to existing data, a fair share of responsibility for the development of these symptoms lies with the distal (vesicular) curl of the internal stent, especially if the technology of its installation is not followed or the length of the drainage is incorrectly selected. The review describes methods for correct installation of internal ureteral stents by transurethral retrograde, antegrade, and laparoscopic approaches, as well as a method for installing and removing mono-pigtail drains. The internal drainage procedure is standard, so the focus is on the nuances and details of this widespread manipulation. The given cohort of patients and the range of surgical interventions indicate a significant experience of the authors in this issue. All illustrations are author's own and taken from the daily workflow. It should be noted that the modern understanding of the process and technological equipment ensure correct stenting when performing any interventions with any access. An adequate choice of installation method and correct positioning of the stent, knowledge of simple details and "secrets" allow not only to restore urodynamics, but also to effectively prevent the development of stent-dependent symptoms, thereby preserving patients quality of life.
- 22 December 2020
- Published by QUASAR, LLC in Research and Practical Medicine Journal
- Vol. 7 (4) , 105-117
Open AccessStenting of the upper urinary tract: from bottom, from top, from side...
Internal stenting of the upper urinary tract is a widespread urological surgery. Its frequency in modern practice is high and continues to grow due to the widespread use of endourological, percutaneous, and laparoscopic interventions. The presence of a stent in the patient's body often leads to a decrease in the quality of life due to the occurrence of stent-dependent symptoms, which often requires urgent hospitalization. According to various data, they are registered in at least 80% of patients. The most common stent-dependent symptoms are frequent and / or painful urination, urge to mix (up to imperative), nocturia, pain in the lumbar region, macrohematuria. According to existing data, a fair share of responsibility for the development of these symptoms lies with the distal (vesicular) curl of the internal stent, especially if the technology of its installation is not followed or the length of the drainage is incorrectly selected. The review describes methods for correct installation of internal ureteral stents by transurethral retrograde, antegrade, and laparoscopic approaches, as well as a method for installing and removing mono-pigtail drains. The internal drainage procedure is standard, so the focus is on the nuances and details of this widespread manipulation. The given cohort of patients and the range of surgical interventions indicate a significant experience of the authors in this issue. All illustrations are author's own and taken from the daily workflow. It should be noted that the modern understanding of the process and technological equipment ensure correct stenting when performing any interventions with any access. An adequate choice of installation method and correct positioning of the stent, knowledge of simple details and "secrets" allow not only to restore urodynamics, but also to effectively prevent the development of stent-dependent symptoms, thereby preserving patients quality of life.
- 29 September 2020
- Published by UroMedia LLC in Experimental and Сlinical Urology
- Vol. 12 (3)
Modern treatment of urinary stone disease: results improvement in the spotlight
- 29 September 2020
- Published by UroMedia LLC in Experimental and Сlinical Urology
- Vol. 12 (3)
Modern treatment of urinary stone disease: results improvement in the spotlight
- 29 July 2019
- Published by UroMedia LLC in Experimental and Сlinical Urology
- Vol. 11 (2)
Selection of drug therapy in patients after bipolar transurethral resection of the prostate depending on its original size
- 29 July 2019
- Published by UroMedia LLC in Experimental and Сlinical Urology
- Vol. 11 (2)
Selection of drug therapy in patients after bipolar transurethral resection of the prostate depending on its original size